The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascert...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wang, Tzu-Fei, Ahluwalia, Rohan, Fiala, Mark A., Trinkaus, Kathryn M., Cox, Doug P., Jaenicke, Matthew, Moliske, Caitlin C., Carson, Kenneth R., Wildes, Tanya M., Tomasson, Michael H., Stockerl-Goldstein, Keith E., Vij, Ravi
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3951876/
https://ncbi.nlm.nih.gov/pubmed/23662990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.803547
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi